PHARVARIS NV (PHVS) Stock News

USA - NASDAQ:PHVS - NL00150005Y4 - Common Stock

21.53 USD

-0.06 (-0.28%)

Last: 11/10/2025, 11:14:17 AM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

PHVS Latest News, Press Relases and Analysis

All

Press Releases

5 hours ago - By: Pharvaris N.V.

Data Supporting the Potentially Differentiated Pharvaris Portfolio Presented at ACAAI 2025 Annual Scientific Meeting

5 hours ago - By: Pharvaris N.V.

Data Supporting the Potentially Differentiated Pharvaris Portfolio Presented at ACAAI 2025 Annual Scientific Meeting

18 days ago - By: Pharvaris N.V.

Pharvaris to Present Clinical Data at the ACAAI 2025 Annual Scientific Meeting

18 days ago - By: Pharvaris N.V.

Pharvaris to Present Clinical Data at the ACAAI 2025 Annual Scientific Meeting

6 months ago - By: Pharvaris N.V.

Pharvaris Reports First Quarter 2025 Financial Results and Provides Business Update

a month ago - By: Benzinga - Mentions: EQT NKE WMT UBER

This Uber Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

3 months ago - By: Pharvaris N.V.

Pharvaris Reports Second Quarter 2025 Financial Results and Provides Business Update

4 months ago - By: Pharvaris N.V.

Pharvaris Announces Closing of $201.2 Million Upsized Public Offering of Ordinary Shares and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares

10 months ago - By: Pharvaris N.V.

Pharvaris Outlines 2025 Strategic Priorities

4 months ago - By: Pharvaris N.V.

Pharvaris Announces Closing of $201.2 Million Upsized Public Offering of Ordinary Shares and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares

4 months ago - By: Pharvaris N.V.

Pharvaris Announces Pricing of Upsized $175 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

4 months ago - By: Pharvaris N.V.

Pharvaris Announces Pricing of Upsized $175 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

4 months ago - By: Pharvaris N.V.

Pharvaris Announces Proposed Public Offering of Ordinary Shares

4 months ago - By: Pharvaris N.V.

Pharvaris Announces Proposed Public Offering of Ordinary Shares

4 months ago - By: Pharvaris N.V.

Pharvaris Updates Timing of Topline Data Announcement for RAPIDe-3 Pivotal Phase 3 Study to the Fourth Quarter of 2025

4 months ago - By: Pharvaris N.V.

Pharvaris Updates Timing of Topline Data Announcement for RAPIDe-3 Pivotal Phase 3 Study to the Fourth Quarter of 2025

5 months ago - By: Pharvaris N.V.

Pharvaris Announces Clinical Trial Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2025 US HAEA National Summit

5 months ago - By: Pharvaris N.V.

Pharvaris Announces Clinical Trial Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2025 US HAEA National Summit

5 months ago - By: Pharvaris N.V.

Pharvaris Presents Data Highlighting the Potential for Deucrictibant to Prevent and Treat Bradykinin-Mediated Angioedema Attacks at the EAACI Congress

5 months ago - By: Pharvaris N.V.

Pharvaris Presents Data Highlighting the Potential for Deucrictibant to Prevent and Treat Bradykinin-Mediated Angioedema Attacks at the EAACI Congress

5 months ago - By: Pharvaris N.V.

Pharvaris Announces Annual Meeting of Shareholders

5 months ago - By: Pharvaris N.V.

Pharvaris Announces Annual Meeting of Shareholders

5 months ago - By: Pharvaris N.V.

Pharvaris Presents Data Supporting Ongoing Clinical Development of Deucrictibant in Bradykinin-Mediated Angioedema

5 months ago - By: Pharvaris N.V.

Pharvaris Presents Data Supporting Ongoing Clinical Development of Deucrictibant in Bradykinin-Mediated Angioedema

6 months ago - By: Pharvaris N.V.

Pharvaris to Present Deucrictibant Clinical Data and Exploratory Biomarker Data at Upcoming Congresses

6 months ago - By: Pharvaris N.V.

Pharvaris to Present Deucrictibant Clinical Data and Exploratory Biomarker Data at Upcoming Congresses

6 months ago - By: Pharvaris N.V.

Pharvaris Reports First Quarter 2025 Financial Results and Provides Business Update

6 months ago - By: Pharvaris N.V.

Pharvaris to Host a Virtual R&D Call “Deucrictibant: Beyond HAE Type 1/2” on June 4

6 months ago - By: Pharvaris N.V.

Pharvaris to Host a Virtual R&D Call “Deucrictibant: Beyond HAE Type 1/2” on June 4

7 months ago - By: Pharvaris N.V.

Pharvaris Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

7 months ago - By: Pharvaris N.V.

Pharvaris Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

7 months ago - By: Pharvaris N.V.

Pharvaris Announces Orphan Designation Granted to Deucrictibant by the European Commission

7 months ago - By: Pharvaris N.V.

Pharvaris Announces Orphan Designation Granted to Deucrictibant by the European Commission

8 months ago - By: Pharvaris N.V.

Pharvaris Presents Long-Term Clinical Data of Deucrictibant for the Prevention and Treatment of HAE Attacks at the 2025 AAAAI/WAO Joint Congress

8 months ago - By: Pharvaris N.V.

Pharvaris Presents Long-Term Clinical Data of Deucrictibant for the Prevention and Treatment of HAE Attacks at the 2025 AAAAI/WAO Joint Congress

8 months ago - By: Pharvaris N.V.

Pharvaris to Participate in the Leerink Partners Global Healthcare Conference 2025

8 months ago - By: Pharvaris N.V.

Pharvaris to Participate in the Leerink Partners Global Healthcare Conference 2025